Antić, Darko

Link to this page

Authority KeyName Variants
orcid::0000-0002-2608-1342
  • Antić, Darko (21)
Projects

Author's Bibliography

Activation of coagulation factors and prothrombic properties of endothelium in hematological malignancies

Mitrović-Ajtić, Olivera; Đikić, Dragoslava; Dragojević, Teodora; Otašević, Vladimir; Živković, Emilija; Vuković, Vojin; Vukotić, Milica; Subotički, Tijana; Diklić, Miloš; Suvajdžić-Vuković, Nada; Mitrović, Mirjana; Mihaljević, Biljana; Antić, Darko; Čokić, Vladan

(Belgrade: Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade, 2023)

TY  - CONF
AU  - Mitrović-Ajtić, Olivera
AU  - Đikić, Dragoslava
AU  - Dragojević, Teodora
AU  - Otašević, Vladimir
AU  - Živković, Emilija
AU  - Vuković, Vojin
AU  - Vukotić, Milica
AU  - Subotički, Tijana
AU  - Diklić, Miloš
AU  - Suvajdžić-Vuković, Nada
AU  - Mitrović, Mirjana
AU  - Mihaljević, Biljana
AU  - Antić, Darko
AU  - Čokić, Vladan
PY  - 2023
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1420
AB  - Introduction: Patients with hematological malignancies have an increased risk of thrombotic complications, ranging from 3-5% in patients with lymphoma and acute myeloid leukemia (AML). The presented study observed the onset of thrombus formation to predict risk factors for thrombosis in lymphoid and myeloid malignancies. Methods: Coagulation factors, inflammatory signaling pathways and adhesion molecules have been observed in patients with Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and AML. Their mononuclear cells (MNC) trans-endothelial migration through human microvascular endothelial cells (HMEC-1) monolayer is observed by Boyden chamber.
Results: Thrombin was in positive correlation with tumor necrosis factor alpha (TNF-α) in HL, while with P-selectin (p<0.001), tumor growth factor-beta (TGF-β) and factor VIII (p<0.05) in DLBCL and AML. Transendothelial migration of MNC was increased by TNF-α (p<0.001) in DLBCL regardless of previous thrombosis. Regarding coagulation, factor VIII was increased in HL and AML (p<0.05), while tissue factor in non-Hodgkin lymphomas (DLBCL and FL, p<0.05). Tissue factor was in positive correlation with adhesion molecule P-selectin and factor VIII (p<0.05). P-selectin was increased in non-Hodgkin lymphomas (p<0.0001), while TGF-β only in FL (p<0.001). Fibrinolytic activity was decreased in plasma of patients with HL, DLBCL, and FL (p<0.05), but largely in AML (p<0.01) as measured by tissue-type plasminogen activator. Inflammatory NF-κB signaling has been activated in HL and DLBCL, while p38 signaling only in HL. Conclusion: Coagulation factors and inflammation are increased in hematological malignancies along with the interaction of the endothelium and circulating cells that predispose to thrombus formation
PB  - Belgrade: Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade
C3  - CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
T1  - Activation of coagulation factors and prothrombic properties of endothelium in hematological malignancies
EP  - 134
SP  - 134
UR  - https://hdl.handle.net/21.15107/rcub_rimi_1420
ER  - 
@conference{
author = "Mitrović-Ajtić, Olivera and Đikić, Dragoslava and Dragojević, Teodora and Otašević, Vladimir and Živković, Emilija and Vuković, Vojin and Vukotić, Milica and Subotički, Tijana and Diklić, Miloš and Suvajdžić-Vuković, Nada and Mitrović, Mirjana and Mihaljević, Biljana and Antić, Darko and Čokić, Vladan",
year = "2023",
abstract = "Introduction: Patients with hematological malignancies have an increased risk of thrombotic complications, ranging from 3-5% in patients with lymphoma and acute myeloid leukemia (AML). The presented study observed the onset of thrombus formation to predict risk factors for thrombosis in lymphoid and myeloid malignancies. Methods: Coagulation factors, inflammatory signaling pathways and adhesion molecules have been observed in patients with Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and AML. Their mononuclear cells (MNC) trans-endothelial migration through human microvascular endothelial cells (HMEC-1) monolayer is observed by Boyden chamber.
Results: Thrombin was in positive correlation with tumor necrosis factor alpha (TNF-α) in HL, while with P-selectin (p<0.001), tumor growth factor-beta (TGF-β) and factor VIII (p<0.05) in DLBCL and AML. Transendothelial migration of MNC was increased by TNF-α (p<0.001) in DLBCL regardless of previous thrombosis. Regarding coagulation, factor VIII was increased in HL and AML (p<0.05), while tissue factor in non-Hodgkin lymphomas (DLBCL and FL, p<0.05). Tissue factor was in positive correlation with adhesion molecule P-selectin and factor VIII (p<0.05). P-selectin was increased in non-Hodgkin lymphomas (p<0.0001), while TGF-β only in FL (p<0.001). Fibrinolytic activity was decreased in plasma of patients with HL, DLBCL, and FL (p<0.05), but largely in AML (p<0.01) as measured by tissue-type plasminogen activator. Inflammatory NF-κB signaling has been activated in HL and DLBCL, while p38 signaling only in HL. Conclusion: Coagulation factors and inflammation are increased in hematological malignancies along with the interaction of the endothelium and circulating cells that predispose to thrombus formation",
publisher = "Belgrade: Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade",
journal = "CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia",
title = "Activation of coagulation factors and prothrombic properties of endothelium in hematological malignancies",
pages = "134-134",
url = "https://hdl.handle.net/21.15107/rcub_rimi_1420"
}
Mitrović-Ajtić, O., Đikić, D., Dragojević, T., Otašević, V., Živković, E., Vuković, V., Vukotić, M., Subotički, T., Diklić, M., Suvajdžić-Vuković, N., Mitrović, M., Mihaljević, B., Antić, D.,& Čokić, V.. (2023). Activation of coagulation factors and prothrombic properties of endothelium in hematological malignancies. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
Belgrade: Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade., 134-134.
https://hdl.handle.net/21.15107/rcub_rimi_1420
Mitrović-Ajtić O, Đikić D, Dragojević T, Otašević V, Živković E, Vuković V, Vukotić M, Subotički T, Diklić M, Suvajdžić-Vuković N, Mitrović M, Mihaljević B, Antić D, Čokić V. Activation of coagulation factors and prothrombic properties of endothelium in hematological malignancies. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia. 2023;:134-134.
https://hdl.handle.net/21.15107/rcub_rimi_1420 .
Mitrović-Ajtić, Olivera, Đikić, Dragoslava, Dragojević, Teodora, Otašević, Vladimir, Živković, Emilija, Vuković, Vojin, Vukotić, Milica, Subotički, Tijana, Diklić, Miloš, Suvajdžić-Vuković, Nada, Mitrović, Mirjana, Mihaljević, Biljana, Antić, Darko, Čokić, Vladan, "Activation of coagulation factors and prothrombic properties of endothelium in hematological malignancies" in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia (2023):134-134,
https://hdl.handle.net/21.15107/rcub_rimi_1420 .

P1653: Inflammation mediated thrombus formation in lymphomas

Antić, Darko; Mitrović Ajtić, Olivera; Đikić, Dragoslava; Otašević, Vladimir; Živković, Emilija; Ivanović, Jelena; Vuković, Vojin; Vukotić, Milica; Šarac, Sofija; MIhajljević, Biljana; Čokić, Vladan

(Wolters Kluwer Health, Inc., 2023)

TY  - CONF
AU  - Antić, Darko
AU  - Mitrović Ajtić, Olivera
AU  - Đikić, Dragoslava
AU  - Otašević, Vladimir
AU  - Živković, Emilija
AU  - Ivanović, Jelena
AU  - Vuković, Vojin
AU  - Vukotić, Milica
AU  - Šarac, Sofija
AU  - MIhajljević, Biljana
AU  - Čokić, Vladan
PY  - 2023
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1426
AB  - Background: Patients with lymphomas increased the risk of thrombotic complications, especially in diagnosis and during chemotherapy treatment, in the range of 2.9-4.2%.
Aims: Our hypothesis is that inflammation and provoked immunity are responsible for generation of thrombus due to disturbed balance between coagulation and fibrinolysis.
Methods: Quantification of neutrophil extracellular traps (NETs) from peripheral blood of 80 patients with Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL) measuring circulating cell-free DNA (cfDNA) and myeloperoxidase (MPO) activity. The inflammatory cytokines, coagulation factors and chemokines are measured by enzyme-linked immunosorbent assay (ELISA) and flow cytometry in peripheral blood, while fibrinolytic activity by fluorescent tissue-type plasminogen activator (tPA) and urokinase plasminogen activator (uPA) assays. Using a Boyden chamber, trans-endothelial migration of mononuclear cells (MNC) across a monolayer of human microvascular endothelial cells (HMEC-1) will be observed.
Results: The pro-inflammatory cytokines IL-1β and TNF-α were significantly increased in DLBCL and HL, but not the chemokines IL-8 and MCP-1. NETs were increased in the peripheral blood of patients with HL (p<0.05) as measured by cfDNA and MPO activity. In contrast, cfDNA was largely reduced in DLBCL with thrombosis (p<0.001). Trans-endothelial migration of MNC was decreased by IL-6, but increased by TNF-α (p<0.001) in DLBCL with thrombosis. In the absence of thrombosis, MNC of HL demonstrated increased trans-endothelial migration in the presence of pro-inflammatory IL-6 (p<0.01), while MNC of HL and DLBCL in the presence of TNF-α (p<0.05). Regarding coagulation, factor VIII was increased in HL (p<0.05), while tissue factor in non-Hodgkin lymphomas (DLBCL and FL, p<0.05). Adhesion molecule P-selectin was increased in lymphomas, mostly in non-Hodgkin lymphomas (p<0.0001), while TGF-β is only in FL (p<0.001). Fibrinogen was negatively correlated with cfDNA (p=0.021, r=-0.767) in HL, while in positive correlation with TNF-α (p=0.028, r=0.517), IL-8 (p=0.009, r=0.598) and MCP-1 (p=0.004, r=0.643) in FL and with TGF-β (p=0.007, r=0.748) in HL. In opposite to uPA, fibrinolytic activity was decreased in the plasma of patients with HL, DLBCL, and FL (p<0.05) as measured by tPA. The tPA was in negative correlation with MPO in HL (p=0.017, r=-0.783) and FL (p=0.006, r=-0.818), while positively correlated with cfDNA in DLBCL (p=0.034, r=0.402, Table 1). The uPA was in positive correlation with cfDNA (p=0.009, r=0.692) and fibrinogen (p=0.009, r=0.692) in FL. Tissue factor (CD142+) procoagulant microparticles derived from monocytes (CD14+: 7.49±0.2, p<0.001) and activated monocytes (CD14+/CD16+: 3.75±0.8%, p<0.05) were increased in DLBCL compared to healthy controls.
Summary/Conclusion: Chronic inflammation is present in the examined lymphomas where TNF-α, as an activator of the immune response, is linked with the initiation of thrombus formation. Moreover, augmented innate immunity is accompanied by procoagulants that mutually support thrombosis.
F1
PB  - Wolters Kluwer Health, Inc.
C3  - HemaSphere - EHA2023 Hybrid Congress Abstract Book S3
T1  - P1653: Inflammation mediated thrombus formation in lymphomas
EP  - 3213
IS  - 7(S)
SP  - 3212
DO  - 10.1097/01.HS9.0000973484.54165.7a
ER  - 
@conference{
author = "Antić, Darko and Mitrović Ajtić, Olivera and Đikić, Dragoslava and Otašević, Vladimir and Živković, Emilija and Ivanović, Jelena and Vuković, Vojin and Vukotić, Milica and Šarac, Sofija and MIhajljević, Biljana and Čokić, Vladan",
year = "2023",
abstract = "Background: Patients with lymphomas increased the risk of thrombotic complications, especially in diagnosis and during chemotherapy treatment, in the range of 2.9-4.2%.
Aims: Our hypothesis is that inflammation and provoked immunity are responsible for generation of thrombus due to disturbed balance between coagulation and fibrinolysis.
Methods: Quantification of neutrophil extracellular traps (NETs) from peripheral blood of 80 patients with Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL) measuring circulating cell-free DNA (cfDNA) and myeloperoxidase (MPO) activity. The inflammatory cytokines, coagulation factors and chemokines are measured by enzyme-linked immunosorbent assay (ELISA) and flow cytometry in peripheral blood, while fibrinolytic activity by fluorescent tissue-type plasminogen activator (tPA) and urokinase plasminogen activator (uPA) assays. Using a Boyden chamber, trans-endothelial migration of mononuclear cells (MNC) across a monolayer of human microvascular endothelial cells (HMEC-1) will be observed.
Results: The pro-inflammatory cytokines IL-1β and TNF-α were significantly increased in DLBCL and HL, but not the chemokines IL-8 and MCP-1. NETs were increased in the peripheral blood of patients with HL (p<0.05) as measured by cfDNA and MPO activity. In contrast, cfDNA was largely reduced in DLBCL with thrombosis (p<0.001). Trans-endothelial migration of MNC was decreased by IL-6, but increased by TNF-α (p<0.001) in DLBCL with thrombosis. In the absence of thrombosis, MNC of HL demonstrated increased trans-endothelial migration in the presence of pro-inflammatory IL-6 (p<0.01), while MNC of HL and DLBCL in the presence of TNF-α (p<0.05). Regarding coagulation, factor VIII was increased in HL (p<0.05), while tissue factor in non-Hodgkin lymphomas (DLBCL and FL, p<0.05). Adhesion molecule P-selectin was increased in lymphomas, mostly in non-Hodgkin lymphomas (p<0.0001), while TGF-β is only in FL (p<0.001). Fibrinogen was negatively correlated with cfDNA (p=0.021, r=-0.767) in HL, while in positive correlation with TNF-α (p=0.028, r=0.517), IL-8 (p=0.009, r=0.598) and MCP-1 (p=0.004, r=0.643) in FL and with TGF-β (p=0.007, r=0.748) in HL. In opposite to uPA, fibrinolytic activity was decreased in the plasma of patients with HL, DLBCL, and FL (p<0.05) as measured by tPA. The tPA was in negative correlation with MPO in HL (p=0.017, r=-0.783) and FL (p=0.006, r=-0.818), while positively correlated with cfDNA in DLBCL (p=0.034, r=0.402, Table 1). The uPA was in positive correlation with cfDNA (p=0.009, r=0.692) and fibrinogen (p=0.009, r=0.692) in FL. Tissue factor (CD142+) procoagulant microparticles derived from monocytes (CD14+: 7.49±0.2, p<0.001) and activated monocytes (CD14+/CD16+: 3.75±0.8%, p<0.05) were increased in DLBCL compared to healthy controls.
Summary/Conclusion: Chronic inflammation is present in the examined lymphomas where TNF-α, as an activator of the immune response, is linked with the initiation of thrombus formation. Moreover, augmented innate immunity is accompanied by procoagulants that mutually support thrombosis.
F1",
publisher = "Wolters Kluwer Health, Inc.",
journal = "HemaSphere - EHA2023 Hybrid Congress Abstract Book S3",
title = "P1653: Inflammation mediated thrombus formation in lymphomas",
pages = "3213-3212",
number = "7(S)",
doi = "10.1097/01.HS9.0000973484.54165.7a"
}
Antić, D., Mitrović Ajtić, O., Đikić, D., Otašević, V., Živković, E., Ivanović, J., Vuković, V., Vukotić, M., Šarac, S., MIhajljević, B.,& Čokić, V.. (2023). P1653: Inflammation mediated thrombus formation in lymphomas. in HemaSphere - EHA2023 Hybrid Congress Abstract Book S3
Wolters Kluwer Health, Inc..(7(S)), 3212-3213.
https://doi.org/10.1097/01.HS9.0000973484.54165.7a
Antić D, Mitrović Ajtić O, Đikić D, Otašević V, Živković E, Ivanović J, Vuković V, Vukotić M, Šarac S, MIhajljević B, Čokić V. P1653: Inflammation mediated thrombus formation in lymphomas. in HemaSphere - EHA2023 Hybrid Congress Abstract Book S3. 2023;(7(S)):3212-3213.
doi:10.1097/01.HS9.0000973484.54165.7a .
Antić, Darko, Mitrović Ajtić, Olivera, Đikić, Dragoslava, Otašević, Vladimir, Živković, Emilija, Ivanović, Jelena, Vuković, Vojin, Vukotić, Milica, Šarac, Sofija, MIhajljević, Biljana, Čokić, Vladan, "P1653: Inflammation mediated thrombus formation in lymphomas" in HemaSphere - EHA2023 Hybrid Congress Abstract Book S3, no. 7(S) (2023):3212-3213,
https://doi.org/10.1097/01.HS9.0000973484.54165.7a . .

PB2162: Increased oxidative stress in diffuse large B-cell lymphoma

Antić, Darko; Đikić, Dragoslava; Otašević, Vladimir; Mitrović-Ajtić, Olivera; Vuković, Vojin; Subotički, Tijana; Đurašinović, Vladislava; Tomić, Kristina; Mihaljević, Biljana; Čokić, Vladan

(Wolters Kluwer Health, Inc, 2022)

TY  - CONF
AU  - Antić, Darko
AU  - Đikić, Dragoslava
AU  - Otašević, Vladimir
AU  - Mitrović-Ajtić, Olivera
AU  - Vuković, Vojin
AU  - Subotički, Tijana
AU  - Đurašinović, Vladislava
AU  - Tomić, Kristina
AU  - Mihaljević, Biljana
AU  - Čokić, Vladan
PY  - 2022
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1428
AB  - Background: Oxidative stress is caused by imbalance between excessive production of reactive oxygen species and decreased capabilities of antioxidant system, and it is recognized as a feature in cancerogenesis, as well in hematologic malignancies. Previous studies have shown increasing expression of oxidative stress markers and antioxidant enzymes in lymph nodes progressing to aggressive lymphomas.
Aims: The aim of our study was to assess the clinical and prognostic significance of oxidative stress markers in patients with untreated diffuse large B-cell lymphoma (DLBCL).
Methods: We analysed 64 patients diagnosed with DLBLC during 2018 and 2019, while 27 healthy volunteers (51.9% males) served as a control group. The plasma sample and laboratory analyses were obtained prior to initiation of specific hematologic treatment. After completion of the therapy, the patients were followed up for up to 4 years and for each of them progression free survival (PFS) and overall survival (OS) were calculated. Malondialdehyde (MDA) and protein carbonyl (PC) were used as markers of oxidative stress in plasma of patients and volunteers, while catalase is used as an antioxidant marker.
Results: The mean patients’ age was 56.2 years (range, 20–87); 51.6% were males. Majority of patients were analysed before 1L therapy (n=61; 95,3%), and had following clinical stages: Ann Arbor stage I 23.4%, stage II 37.5%, stage III 15.6% and stage IV 23.4%. Majority of the patients had satisfactory performance status (73.5% had ECOG PS ≥1), bulky tumorous mass was present in 34.4% of patients, whereas 70.3% had extranodal localisation of lymphoma. MDA (6.66±2.7 nmol/ml) was significantly increased (p<0.001, 2.6-fold), while PC (4.29±2.7 nmol/mg) was also significantly increased (p=0.0027, 5-fold) in patients with DLBCL compared to healthy volunteers. In opposite, antioxidant catalase (0.194±0.06 IU/ml) was significantly reduced (p=0.0034, 1.9-fold) in patients with DLBCL. MDA was in significant (p<0.05) negative correlation with hemoglobin (r2=0.586) and LDH (r2=0.59) levels before chemotherapy. MDA was in significant (p<0.01) positive correlation with the age (r2=0.769) of patients with DLBCL at diagnosis. Moreover, MDA was in significant positive correlation with overall survival (p<0.01, r2=0.736) and progression-free survival (p<0.01, r2=0.736) of patients with DLBCL. PC was in negative correlation with the clinical stage (r2=0.103, p=0.146) and therapy response (r2=0.136, p=0.091) of DLBCL but did not reach significance.
Summary/Conclusion: The elevated oxidative markers and reduced antioxidant support oxidative stress in patients with DLBCL, while MDA can be a prognostic marker of overall survival.
PB  - Wolters Kluwer Health, Inc
C3  - HemaSphere - EHA2022 Hybrid Congress Abstract Book
T1  - PB2162: Increased oxidative stress in diffuse large B-cell lymphoma
EP  - 2033
IS  - S3
SP  - 2032
VL  - 6
DO  - 10.1097/01.HS9.0000851476.12536.06
ER  - 
@conference{
author = "Antić, Darko and Đikić, Dragoslava and Otašević, Vladimir and Mitrović-Ajtić, Olivera and Vuković, Vojin and Subotički, Tijana and Đurašinović, Vladislava and Tomić, Kristina and Mihaljević, Biljana and Čokić, Vladan",
year = "2022",
abstract = "Background: Oxidative stress is caused by imbalance between excessive production of reactive oxygen species and decreased capabilities of antioxidant system, and it is recognized as a feature in cancerogenesis, as well in hematologic malignancies. Previous studies have shown increasing expression of oxidative stress markers and antioxidant enzymes in lymph nodes progressing to aggressive lymphomas.
Aims: The aim of our study was to assess the clinical and prognostic significance of oxidative stress markers in patients with untreated diffuse large B-cell lymphoma (DLBCL).
Methods: We analysed 64 patients diagnosed with DLBLC during 2018 and 2019, while 27 healthy volunteers (51.9% males) served as a control group. The plasma sample and laboratory analyses were obtained prior to initiation of specific hematologic treatment. After completion of the therapy, the patients were followed up for up to 4 years and for each of them progression free survival (PFS) and overall survival (OS) were calculated. Malondialdehyde (MDA) and protein carbonyl (PC) were used as markers of oxidative stress in plasma of patients and volunteers, while catalase is used as an antioxidant marker.
Results: The mean patients’ age was 56.2 years (range, 20–87); 51.6% were males. Majority of patients were analysed before 1L therapy (n=61; 95,3%), and had following clinical stages: Ann Arbor stage I 23.4%, stage II 37.5%, stage III 15.6% and stage IV 23.4%. Majority of the patients had satisfactory performance status (73.5% had ECOG PS ≥1), bulky tumorous mass was present in 34.4% of patients, whereas 70.3% had extranodal localisation of lymphoma. MDA (6.66±2.7 nmol/ml) was significantly increased (p<0.001, 2.6-fold), while PC (4.29±2.7 nmol/mg) was also significantly increased (p=0.0027, 5-fold) in patients with DLBCL compared to healthy volunteers. In opposite, antioxidant catalase (0.194±0.06 IU/ml) was significantly reduced (p=0.0034, 1.9-fold) in patients with DLBCL. MDA was in significant (p<0.05) negative correlation with hemoglobin (r2=0.586) and LDH (r2=0.59) levels before chemotherapy. MDA was in significant (p<0.01) positive correlation with the age (r2=0.769) of patients with DLBCL at diagnosis. Moreover, MDA was in significant positive correlation with overall survival (p<0.01, r2=0.736) and progression-free survival (p<0.01, r2=0.736) of patients with DLBCL. PC was in negative correlation with the clinical stage (r2=0.103, p=0.146) and therapy response (r2=0.136, p=0.091) of DLBCL but did not reach significance.
Summary/Conclusion: The elevated oxidative markers and reduced antioxidant support oxidative stress in patients with DLBCL, while MDA can be a prognostic marker of overall survival.",
publisher = "Wolters Kluwer Health, Inc",
journal = "HemaSphere - EHA2022 Hybrid Congress Abstract Book",
title = "PB2162: Increased oxidative stress in diffuse large B-cell lymphoma",
pages = "2033-2032",
number = "S3",
volume = "6",
doi = "10.1097/01.HS9.0000851476.12536.06"
}
Antić, D., Đikić, D., Otašević, V., Mitrović-Ajtić, O., Vuković, V., Subotički, T., Đurašinović, V., Tomić, K., Mihaljević, B.,& Čokić, V.. (2022). PB2162: Increased oxidative stress in diffuse large B-cell lymphoma. in HemaSphere - EHA2022 Hybrid Congress Abstract Book
Wolters Kluwer Health, Inc., 6(S3), 2032-2033.
https://doi.org/10.1097/01.HS9.0000851476.12536.06
Antić D, Đikić D, Otašević V, Mitrović-Ajtić O, Vuković V, Subotički T, Đurašinović V, Tomić K, Mihaljević B, Čokić V. PB2162: Increased oxidative stress in diffuse large B-cell lymphoma. in HemaSphere - EHA2022 Hybrid Congress Abstract Book. 2022;6(S3):2032-2033.
doi:10.1097/01.HS9.0000851476.12536.06 .
Antić, Darko, Đikić, Dragoslava, Otašević, Vladimir, Mitrović-Ajtić, Olivera, Vuković, Vojin, Subotički, Tijana, Đurašinović, Vladislava, Tomić, Kristina, Mihaljević, Biljana, Čokić, Vladan, "PB2162: Increased oxidative stress in diffuse large B-cell lymphoma" in HemaSphere - EHA2022 Hybrid Congress Abstract Book, 6, no. S3 (2022):2032-2033,
https://doi.org/10.1097/01.HS9.0000851476.12536.06 . .

Regulation of S100As Expression by Inflammatory Cytokines in Chronic Lymphocytic Leukemia

Mitrović-Ajtić, Olivera; Subotički, Tijana; Diklić, Miloš; Đikić, Dragoslava; Vukotić, Milica; Dragojević, Teodora; Živković, Emilija; Antić, Darko; Čokić, Vladan

(MDPI, 2022)

TY  - JOUR
AU  - Mitrović-Ajtić, Olivera
AU  - Subotički, Tijana
AU  - Diklić, Miloš
AU  - Đikić, Dragoslava
AU  - Vukotić, Milica
AU  - Dragojević, Teodora
AU  - Živković, Emilija
AU  - Antić, Darko
AU  - Čokić, Vladan
PY  - 2022
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1244
AB  - The calcium-binding proteins S100A4, S100A8, and S100A9 are upregulated in chronic lymphocytic leukemia (CLL), while the S100A9 promotes NF-κB activity during disease progression. The S100-protein family has been involved in several malignancies as mediators of inflammation and proliferation. The hypothesis of our study is that S100A proteins are mediators in signaling pathways associated with inflammation-induced proliferation, such as NF-κB, PI3K/AKT, and JAK/STAT. The mononuclear cells (MNCs) of CLL were treated with proinflammatory IL-6, anti-inflammatory IL-10 cytokines, inhibitors of JAK1/2, NF-κB, and PI3K signaling pathways, to evaluate S100A4, S100A8, S100A9, and S100A12 expression as well as NF-κB activation by qRT-PCR, immunocytochemistry, and immunoblotting. The quantity of S100A4, S100A8, and S100A9 positive cells (p < 0.05) and their protein expression (p < 0.01) were significantly decreased in MNCs of CLL patients compared to healthy controls. The S100A levels were generally increased in CD19+ cells compared to MNCs of CLL. The S100A4 gene expression was significantly stimulated (p < 0.05) by the inhibition of the PI3K/AKT signaling pathway in MNCs. IL-6 stimulated S100A4 and S100A8 protein expression, prevented by the NF-κB and JAK1/2 inhibitors. In contrast, IL-10 reduced S100A8, S100A9, and S100A12 protein expressions in MNCs of CLL. Moreover, IL-10 inhibited activation of NF-κB signaling (4-fold, p < 0.05). In conclusion, inflammation stimulated the S100A protein expression mediated via the proliferation-related signaling and balanced by the cytokines in CLL.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Regulation of S100As Expression by Inflammatory Cytokines in Chronic Lymphocytic Leukemia
IS  - 13
SP  - 6952
VL  - 23
DO  - 10.3390/ijms23136952
ER  - 
@article{
author = "Mitrović-Ajtić, Olivera and Subotički, Tijana and Diklić, Miloš and Đikić, Dragoslava and Vukotić, Milica and Dragojević, Teodora and Živković, Emilija and Antić, Darko and Čokić, Vladan",
year = "2022",
abstract = "The calcium-binding proteins S100A4, S100A8, and S100A9 are upregulated in chronic lymphocytic leukemia (CLL), while the S100A9 promotes NF-κB activity during disease progression. The S100-protein family has been involved in several malignancies as mediators of inflammation and proliferation. The hypothesis of our study is that S100A proteins are mediators in signaling pathways associated with inflammation-induced proliferation, such as NF-κB, PI3K/AKT, and JAK/STAT. The mononuclear cells (MNCs) of CLL were treated with proinflammatory IL-6, anti-inflammatory IL-10 cytokines, inhibitors of JAK1/2, NF-κB, and PI3K signaling pathways, to evaluate S100A4, S100A8, S100A9, and S100A12 expression as well as NF-κB activation by qRT-PCR, immunocytochemistry, and immunoblotting. The quantity of S100A4, S100A8, and S100A9 positive cells (p < 0.05) and their protein expression (p < 0.01) were significantly decreased in MNCs of CLL patients compared to healthy controls. The S100A levels were generally increased in CD19+ cells compared to MNCs of CLL. The S100A4 gene expression was significantly stimulated (p < 0.05) by the inhibition of the PI3K/AKT signaling pathway in MNCs. IL-6 stimulated S100A4 and S100A8 protein expression, prevented by the NF-κB and JAK1/2 inhibitors. In contrast, IL-10 reduced S100A8, S100A9, and S100A12 protein expressions in MNCs of CLL. Moreover, IL-10 inhibited activation of NF-κB signaling (4-fold, p < 0.05). In conclusion, inflammation stimulated the S100A protein expression mediated via the proliferation-related signaling and balanced by the cytokines in CLL.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Regulation of S100As Expression by Inflammatory Cytokines in Chronic Lymphocytic Leukemia",
number = "13",
pages = "6952",
volume = "23",
doi = "10.3390/ijms23136952"
}
Mitrović-Ajtić, O., Subotički, T., Diklić, M., Đikić, D., Vukotić, M., Dragojević, T., Živković, E., Antić, D.,& Čokić, V.. (2022). Regulation of S100As Expression by Inflammatory Cytokines in Chronic Lymphocytic Leukemia. in International Journal of Molecular Sciences
MDPI., 23(13), 6952.
https://doi.org/10.3390/ijms23136952
Mitrović-Ajtić O, Subotički T, Diklić M, Đikić D, Vukotić M, Dragojević T, Živković E, Antić D, Čokić V. Regulation of S100As Expression by Inflammatory Cytokines in Chronic Lymphocytic Leukemia. in International Journal of Molecular Sciences. 2022;23(13):6952.
doi:10.3390/ijms23136952 .
Mitrović-Ajtić, Olivera, Subotički, Tijana, Diklić, Miloš, Đikić, Dragoslava, Vukotić, Milica, Dragojević, Teodora, Živković, Emilija, Antić, Darko, Čokić, Vladan, "Regulation of S100As Expression by Inflammatory Cytokines in Chronic Lymphocytic Leukemia" in International Journal of Molecular Sciences, 23, no. 13 (2022):6952,
https://doi.org/10.3390/ijms23136952 . .
2
4

Influence of inflammatory cytokines on S100A proteins expression in CLL patients

Mitrović-Ajtić, Olivera; Diklić, Miloš; Antić, Darko; Mihaljević, Biljana; Vuković, Vojin; Otašević, Vladimir; Tomić, Kristina; Čokić, Vladan

(Wolters Kluwer Health, Inc., 2021)

TY  - CONF
AU  - Mitrović-Ajtić, Olivera
AU  - Diklić, Miloš
AU  - Antić, Darko
AU  - Mihaljević, Biljana
AU  - Vuković, Vojin
AU  - Otašević, Vladimir
AU  - Tomić, Kristina
AU  - Čokić, Vladan
PY  - 2021
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1429
AB  - Background: S100A proteins possess a broad range of intra- and extracellular functions. The involvement of these proteins in inflammation-mediated responses is of particular interests, considering that inflammation represents one of the landmarks of malignancy. Processes such as inflammation and cellular stress trigger the release of S100A proteins to extracellular space, interacting with their receptors and activating numerous intracellular signaling pathways, for instance NF-κB and AP1. Through them, S100A proteins take part into regulation of some 
of the most essential cellular processes: cell differentiation, apoptosis, 
inflammation, proliferation, etc.
Aims: The aim of the study is to assess the role of inflammation in activation of S100A proteins via proliferation and inflammation related signaling pathways.
Methods: We observed 60 CLL patients’ samples to isolate mononuclear cells (MNC) and CD19+
 cells. MNC of CLL patients were treated with pro-inflammatory IL-6 and anti-inflammatory IL-10 cytokines, and inhibitors of JAK1/2, NF-κB and PI3K signaling pathways, to evaluate 
S100A4, S100A8, S100A9, S100A12 and NF-κB protein expression by immunoblotting. Also, we used immunocytochemistry to analyse the number of the S100As immunopositive MNC of CLL patients.Results: S100A8 showed higher level of protein expression in MNC and 
CD19+cells in comparison to healthy control. The number of immunopositive S100A4 (p<0.05) and S100A9 cells (p<0.001) was signifi cantly decreased in CD19+cells and MNC, respectively of CLL patients in comparison to healthy control. In addition, S100A4 and S100A9 proteins expression had statistically significant lower level of expression in MNC. Also, IL-6 stimulated expression of S100A8 and S100A4 in MNC of CLL, while the expression of latter one was prevented by NF-κB and JAK1/2 inhibitors. IL-10 reduced expression of S100A8 and S100A12 in MNC of CLL.Summary/Conclusion: Pro-inflammatory IL-6 and anti-inflammatory 
IL-10 cytokines have opposite effect on inflammatory S100A8 protein 
in CLL, with a potential to be a prognostic marker.
PB  - Wolters Kluwer Health, Inc.
C3  - HemaSphere - The Abstract Book of the 26th Congress of the European Hematology Association, EHA2021 Virtual Congress
T1  - Influence of inflammatory cytokines on S100A proteins expression in CLL patients
EP  - 280
IS  - S2
SP  - 280
VL  - 5
DO  - 10.1097/HS9.0000000000000566
ER  - 
@conference{
author = "Mitrović-Ajtić, Olivera and Diklić, Miloš and Antić, Darko and Mihaljević, Biljana and Vuković, Vojin and Otašević, Vladimir and Tomić, Kristina and Čokić, Vladan",
year = "2021",
abstract = "Background: S100A proteins possess a broad range of intra- and extracellular functions. The involvement of these proteins in inflammation-mediated responses is of particular interests, considering that inflammation represents one of the landmarks of malignancy. Processes such as inflammation and cellular stress trigger the release of S100A proteins to extracellular space, interacting with their receptors and activating numerous intracellular signaling pathways, for instance NF-κB and AP1. Through them, S100A proteins take part into regulation of some 
of the most essential cellular processes: cell differentiation, apoptosis, 
inflammation, proliferation, etc.
Aims: The aim of the study is to assess the role of inflammation in activation of S100A proteins via proliferation and inflammation related signaling pathways.
Methods: We observed 60 CLL patients’ samples to isolate mononuclear cells (MNC) and CD19+
 cells. MNC of CLL patients were treated with pro-inflammatory IL-6 and anti-inflammatory IL-10 cytokines, and inhibitors of JAK1/2, NF-κB and PI3K signaling pathways, to evaluate 
S100A4, S100A8, S100A9, S100A12 and NF-κB protein expression by immunoblotting. Also, we used immunocytochemistry to analyse the number of the S100As immunopositive MNC of CLL patients.Results: S100A8 showed higher level of protein expression in MNC and 
CD19+cells in comparison to healthy control. The number of immunopositive S100A4 (p<0.05) and S100A9 cells (p<0.001) was signifi cantly decreased in CD19+cells and MNC, respectively of CLL patients in comparison to healthy control. In addition, S100A4 and S100A9 proteins expression had statistically significant lower level of expression in MNC. Also, IL-6 stimulated expression of S100A8 and S100A4 in MNC of CLL, while the expression of latter one was prevented by NF-κB and JAK1/2 inhibitors. IL-10 reduced expression of S100A8 and S100A12 in MNC of CLL.Summary/Conclusion: Pro-inflammatory IL-6 and anti-inflammatory 
IL-10 cytokines have opposite effect on inflammatory S100A8 protein 
in CLL, with a potential to be a prognostic marker.",
publisher = "Wolters Kluwer Health, Inc.",
journal = "HemaSphere - The Abstract Book of the 26th Congress of the European Hematology Association, EHA2021 Virtual Congress",
title = "Influence of inflammatory cytokines on S100A proteins expression in CLL patients",
pages = "280-280",
number = "S2",
volume = "5",
doi = "10.1097/HS9.0000000000000566"
}
Mitrović-Ajtić, O., Diklić, M., Antić, D., Mihaljević, B., Vuković, V., Otašević, V., Tomić, K.,& Čokić, V.. (2021). Influence of inflammatory cytokines on S100A proteins expression in CLL patients. in HemaSphere - The Abstract Book of the 26th Congress of the European Hematology Association, EHA2021 Virtual Congress
Wolters Kluwer Health, Inc.., 5(S2), 280-280.
https://doi.org/10.1097/HS9.0000000000000566
Mitrović-Ajtić O, Diklić M, Antić D, Mihaljević B, Vuković V, Otašević V, Tomić K, Čokić V. Influence of inflammatory cytokines on S100A proteins expression in CLL patients. in HemaSphere - The Abstract Book of the 26th Congress of the European Hematology Association, EHA2021 Virtual Congress. 2021;5(S2):280-280.
doi:10.1097/HS9.0000000000000566 .
Mitrović-Ajtić, Olivera, Diklić, Miloš, Antić, Darko, Mihaljević, Biljana, Vuković, Vojin, Otašević, Vladimir, Tomić, Kristina, Čokić, Vladan, "Influence of inflammatory cytokines on S100A proteins expression in CLL patients" in HemaSphere - The Abstract Book of the 26th Congress of the European Hematology Association, EHA2021 Virtual Congress, 5, no. S2 (2021):280-280,
https://doi.org/10.1097/HS9.0000000000000566 . .
24
58

Influence of applied CD34+ cell dose on the survival of Hodgkin's lymphoma and multiple myeloma patients following autologous stem cell transplants

Todorović-Balint, Milena; Bila, Jelena; Balint, Bela; Jeličić, Jelena; Đunić, Irena; Antić, Darko; Kraguljac-Kurtović, Nada; Vujić, Dragana; Mihaljević, Biljana

(Military Medical Academy, 2020)

TY  - JOUR
AU  - Todorović-Balint, Milena
AU  - Bila, Jelena
AU  - Balint, Bela
AU  - Jeličić, Jelena
AU  - Đunić, Irena
AU  - Antić, Darko
AU  - Kraguljac-Kurtović, Nada
AU  - Vujić, Dragana
AU  - Mihaljević, Biljana
PY  - 2020
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1256
AB  - Background/Aim. Autologous stem cell transplants (ASCTs) improve the rate of overall survival (OS) in patients with hematological malignancies such as multiple myeloma (MM) after induction chemotherapy, aggressive non-Hodgkin's lymphomas (NHL), and relapsed, chemotherapy-sensitive Hodgkin's lymphoma (HL). The study aim was to evaluate influence of applied CD34+ cell quantity on clinical outcome, as well as early post-transplant and overall survival (OS) of HL and MM patients following ASCT. Methods. This study included a total of 210 patients (90 HL/120 MM) who underwent ASCT. Stem cell (SC) mobilization was accomplished by granulocyte-colony stimulating factor (G-CSF) 10–16 μg/kg body mass (bm) following chemotherapy. For proven poor mobilizers, mobilization with G-CSF (16 μg/kgbm) and Plerixafor (24 or 48 mg) was performed. To our best knowledge, it was the first usage of the Plerixafor in our country in the ASCT-setting. Harvesting was initiated merely at "cut-off-value" of CD34+ cells ≥ 20 × 106/L in peripheral blood with "target-dose" of CD34+ cells ≥ 5 × 106/kgbm in harvest. The CD34+ cell count and viability was determined using flow cytometry. Results. The majority of HL patients (76.7%) were infused with > 5.0 × 106/kgbm CD34+ cells, while 68.3% of MM patients were treated by approximately 4.0–5.4 × 106/kgbm CD34+ dose, respectively. Beneficial response (complete/partial remission) was achieved in 83.3% (HL) and 94.2% (MM) patients. Among parameters that influenced survival of HL patients with positive response to the therapy, multivariate analysis (pre-ASCT performance status, CD34+ cell quantity applied, rapid hematopoietic, i.e. lymphocyte and platelet recovery) indicated that higher CD34+ cell dose used, along with pre-ASCT performance status correlated with superior event-free survival (EFS) and OS following ASCT. In MM patients, multivariate analysis (renal impairment, infused CD34+ cell quantity, early platelet recovery) indicated that the number of CD34+ cells infused was the most important parameter that influenced both EFS and OS after ASCT. Conclusion. Data obtained in this study undoubtedly confirmed that CD34+ cell dose applied is an independent factor that may contribute to superior clinical outcome and OS of HL and MM patients following ASCT.
PB  - Military Medical Academy
T2  - Vojnosanitetski pregled
T1  - Influence of applied CD34+ cell dose on the survival of Hodgkin's lymphoma and multiple myeloma patients following autologous stem cell transplants
EP  - 851
IS  - 8
SP  - 844
VL  - 77
DO  - 10.2298/VSP180808160T
ER  - 
@article{
author = "Todorović-Balint, Milena and Bila, Jelena and Balint, Bela and Jeličić, Jelena and Đunić, Irena and Antić, Darko and Kraguljac-Kurtović, Nada and Vujić, Dragana and Mihaljević, Biljana",
year = "2020",
abstract = "Background/Aim. Autologous stem cell transplants (ASCTs) improve the rate of overall survival (OS) in patients with hematological malignancies such as multiple myeloma (MM) after induction chemotherapy, aggressive non-Hodgkin's lymphomas (NHL), and relapsed, chemotherapy-sensitive Hodgkin's lymphoma (HL). The study aim was to evaluate influence of applied CD34+ cell quantity on clinical outcome, as well as early post-transplant and overall survival (OS) of HL and MM patients following ASCT. Methods. This study included a total of 210 patients (90 HL/120 MM) who underwent ASCT. Stem cell (SC) mobilization was accomplished by granulocyte-colony stimulating factor (G-CSF) 10–16 μg/kg body mass (bm) following chemotherapy. For proven poor mobilizers, mobilization with G-CSF (16 μg/kgbm) and Plerixafor (24 or 48 mg) was performed. To our best knowledge, it was the first usage of the Plerixafor in our country in the ASCT-setting. Harvesting was initiated merely at "cut-off-value" of CD34+ cells ≥ 20 × 106/L in peripheral blood with "target-dose" of CD34+ cells ≥ 5 × 106/kgbm in harvest. The CD34+ cell count and viability was determined using flow cytometry. Results. The majority of HL patients (76.7%) were infused with > 5.0 × 106/kgbm CD34+ cells, while 68.3% of MM patients were treated by approximately 4.0–5.4 × 106/kgbm CD34+ dose, respectively. Beneficial response (complete/partial remission) was achieved in 83.3% (HL) and 94.2% (MM) patients. Among parameters that influenced survival of HL patients with positive response to the therapy, multivariate analysis (pre-ASCT performance status, CD34+ cell quantity applied, rapid hematopoietic, i.e. lymphocyte and platelet recovery) indicated that higher CD34+ cell dose used, along with pre-ASCT performance status correlated with superior event-free survival (EFS) and OS following ASCT. In MM patients, multivariate analysis (renal impairment, infused CD34+ cell quantity, early platelet recovery) indicated that the number of CD34+ cells infused was the most important parameter that influenced both EFS and OS after ASCT. Conclusion. Data obtained in this study undoubtedly confirmed that CD34+ cell dose applied is an independent factor that may contribute to superior clinical outcome and OS of HL and MM patients following ASCT.",
publisher = "Military Medical Academy",
journal = "Vojnosanitetski pregled",
title = "Influence of applied CD34+ cell dose on the survival of Hodgkin's lymphoma and multiple myeloma patients following autologous stem cell transplants",
pages = "851-844",
number = "8",
volume = "77",
doi = "10.2298/VSP180808160T"
}
Todorović-Balint, M., Bila, J., Balint, B., Jeličić, J., Đunić, I., Antić, D., Kraguljac-Kurtović, N., Vujić, D.,& Mihaljević, B.. (2020). Influence of applied CD34+ cell dose on the survival of Hodgkin's lymphoma and multiple myeloma patients following autologous stem cell transplants. in Vojnosanitetski pregled
Military Medical Academy., 77(8), 844-851.
https://doi.org/10.2298/VSP180808160T
Todorović-Balint M, Bila J, Balint B, Jeličić J, Đunić I, Antić D, Kraguljac-Kurtović N, Vujić D, Mihaljević B. Influence of applied CD34+ cell dose on the survival of Hodgkin's lymphoma and multiple myeloma patients following autologous stem cell transplants. in Vojnosanitetski pregled. 2020;77(8):844-851.
doi:10.2298/VSP180808160T .
Todorović-Balint, Milena, Bila, Jelena, Balint, Bela, Jeličić, Jelena, Đunić, Irena, Antić, Darko, Kraguljac-Kurtović, Nada, Vujić, Dragana, Mihaljević, Biljana, "Influence of applied CD34+ cell dose on the survival of Hodgkin's lymphoma and multiple myeloma patients following autologous stem cell transplants" in Vojnosanitetski pregled, 77, no. 8 (2020):844-851,
https://doi.org/10.2298/VSP180808160T . .
7

Cd38 and interleukin 6 gene polymorphism in b-cell chronic lymphocytic leukemia-correlation with clinical and laboratory parametars

Vuković, Vojin; Antić, Darko; Čokić, Vladan; Buač, Marijana; Diklić, Miloš; Todorović-Balint, Milena; Bila, Jelena; Anđelić, Boško; Dencic-Fekete, Marija; Đurašinović, Vladislava; Sretenović, Aleksandra; Jeličić, Jelena; Mihaljević, Biljana

(Ferrata Storti Foundation, Pavia, 2016)

TY  - CONF
AU  - Vuković, Vojin
AU  - Antić, Darko
AU  - Čokić, Vladan
AU  - Buač, Marijana
AU  - Diklić, Miloš
AU  - Todorović-Balint, Milena
AU  - Bila, Jelena
AU  - Anđelić, Boško
AU  - Dencic-Fekete, Marija
AU  - Đurašinović, Vladislava
AU  - Sretenović, Aleksandra
AU  - Jeličić, Jelena
AU  - Mihaljević, Biljana
PY  - 2016
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/751
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - Cd38 and interleukin 6 gene polymorphism in b-cell chronic lymphocytic leukemia-correlation with clinical and laboratory parametars
EP  - 718
SP  - 718
VL  - 101
UR  - https://hdl.handle.net/21.15107/rcub_rimi_751
ER  - 
@conference{
author = "Vuković, Vojin and Antić, Darko and Čokić, Vladan and Buač, Marijana and Diklić, Miloš and Todorović-Balint, Milena and Bila, Jelena and Anđelić, Boško and Dencic-Fekete, Marija and Đurašinović, Vladislava and Sretenović, Aleksandra and Jeličić, Jelena and Mihaljević, Biljana",
year = "2016",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "Cd38 and interleukin 6 gene polymorphism in b-cell chronic lymphocytic leukemia-correlation with clinical and laboratory parametars",
pages = "718-718",
volume = "101",
url = "https://hdl.handle.net/21.15107/rcub_rimi_751"
}
Vuković, V., Antić, D., Čokić, V., Buač, M., Diklić, M., Todorović-Balint, M., Bila, J., Anđelić, B., Dencic-Fekete, M., Đurašinović, V., Sretenović, A., Jeličić, J.,& Mihaljević, B.. (2016). Cd38 and interleukin 6 gene polymorphism in b-cell chronic lymphocytic leukemia-correlation with clinical and laboratory parametars. in Haematologica
Ferrata Storti Foundation, Pavia., 101, 718-718.
https://hdl.handle.net/21.15107/rcub_rimi_751
Vuković V, Antić D, Čokić V, Buač M, Diklić M, Todorović-Balint M, Bila J, Anđelić B, Dencic-Fekete M, Đurašinović V, Sretenović A, Jeličić J, Mihaljević B. Cd38 and interleukin 6 gene polymorphism in b-cell chronic lymphocytic leukemia-correlation with clinical and laboratory parametars. in Haematologica. 2016;101:718-718.
https://hdl.handle.net/21.15107/rcub_rimi_751 .
Vuković, Vojin, Antić, Darko, Čokić, Vladan, Buač, Marijana, Diklić, Miloš, Todorović-Balint, Milena, Bila, Jelena, Anđelić, Boško, Dencic-Fekete, Marija, Đurašinović, Vladislava, Sretenović, Aleksandra, Jeličić, Jelena, Mihaljević, Biljana, "Cd38 and interleukin 6 gene polymorphism in b-cell chronic lymphocytic leukemia-correlation with clinical and laboratory parametars" in Haematologica, 101 (2016):718-718,
https://hdl.handle.net/21.15107/rcub_rimi_751 .

The Effect of Paraprotein on Platelet Aggregation

Đunić, Irena; Elezović, Ivo; Ilić, Vesna; Milošević-Jovčić, Nadežda; Bila, Jelena; Suvajdžić-Vuković, Nada; Antić, Darko; Vidović, Ana; Tomin, Dragica

(John Wiley & Sons Inc, Hoboken, 2014)

TY  - JOUR
AU  - Đunić, Irena
AU  - Elezović, Ivo
AU  - Ilić, Vesna
AU  - Milošević-Jovčić, Nadežda
AU  - Bila, Jelena
AU  - Suvajdžić-Vuković, Nada
AU  - Antić, Darko
AU  - Vidović, Ana
AU  - Tomin, Dragica
PY  - 2014
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/566
AB  - Background Some patients with paraproteinemia have platelet aggregation disorders and the aim of this study was to examine disturbance of platelet aggregation in healthy blood donors by isolated paraprotein in vitro. Methods Using Rivanol, paraprotein was separated from the serum of ten patients with paraproteinemia, who had decreased platelet aggregation with several inducers. Platelet aggregation in ten healthy donors was measured with and without addition of the isolated induced paraprotein. The test was repeated with added human immunoglobulins for intravenous use. Results Average of maximal levels of platelet aggregation has been significantly decreased in plasma rich in platelets (PRP) of healthy donors after addition of paraprotein when inducers are used: adenosine diphosphate (ADP) (P = 0.007), collagen (COL) (P = 0.008), ristocetin (RIS) (P = 0.001), and epinephrine (EPI) (P = 0.002). Average of latent time of platelet aggregation was significantly prolonged in healthy donors after addition of paraprotein with inducers: COL (P = 0.008), RIS (P = 0.008) and EPI (P = 0.006) while addition of human immunoglobulins caused no change in platelet aggregation. In comparison, when human immunoglobulins were added, maximal platelet aggregation and latent time did not change significantly. Paraprotein isolated from patients with paraproteinamia, who had decrease platelet aggregation, had significantly decreased platelet aggregation when added to PRP of healthy donors, in vitro. Conclusion Platelet aggregation was not significantly changed was confirmed with addition of human immunoglobulins.
PB  - John Wiley & Sons Inc, Hoboken
T2  - Journal of Clinical Laboratory Analysis
T1  - The Effect of Paraprotein on Platelet Aggregation
EP  - 146
IS  - 2
SP  - 141
VL  - 28
DO  - 10.1002/jcla.21658
ER  - 
@article{
author = "Đunić, Irena and Elezović, Ivo and Ilić, Vesna and Milošević-Jovčić, Nadežda and Bila, Jelena and Suvajdžić-Vuković, Nada and Antić, Darko and Vidović, Ana and Tomin, Dragica",
year = "2014",
abstract = "Background Some patients with paraproteinemia have platelet aggregation disorders and the aim of this study was to examine disturbance of platelet aggregation in healthy blood donors by isolated paraprotein in vitro. Methods Using Rivanol, paraprotein was separated from the serum of ten patients with paraproteinemia, who had decreased platelet aggregation with several inducers. Platelet aggregation in ten healthy donors was measured with and without addition of the isolated induced paraprotein. The test was repeated with added human immunoglobulins for intravenous use. Results Average of maximal levels of platelet aggregation has been significantly decreased in plasma rich in platelets (PRP) of healthy donors after addition of paraprotein when inducers are used: adenosine diphosphate (ADP) (P = 0.007), collagen (COL) (P = 0.008), ristocetin (RIS) (P = 0.001), and epinephrine (EPI) (P = 0.002). Average of latent time of platelet aggregation was significantly prolonged in healthy donors after addition of paraprotein with inducers: COL (P = 0.008), RIS (P = 0.008) and EPI (P = 0.006) while addition of human immunoglobulins caused no change in platelet aggregation. In comparison, when human immunoglobulins were added, maximal platelet aggregation and latent time did not change significantly. Paraprotein isolated from patients with paraproteinamia, who had decrease platelet aggregation, had significantly decreased platelet aggregation when added to PRP of healthy donors, in vitro. Conclusion Platelet aggregation was not significantly changed was confirmed with addition of human immunoglobulins.",
publisher = "John Wiley & Sons Inc, Hoboken",
journal = "Journal of Clinical Laboratory Analysis",
title = "The Effect of Paraprotein on Platelet Aggregation",
pages = "146-141",
number = "2",
volume = "28",
doi = "10.1002/jcla.21658"
}
Đunić, I., Elezović, I., Ilić, V., Milošević-Jovčić, N., Bila, J., Suvajdžić-Vuković, N., Antić, D., Vidović, A.,& Tomin, D.. (2014). The Effect of Paraprotein on Platelet Aggregation. in Journal of Clinical Laboratory Analysis
John Wiley & Sons Inc, Hoboken., 28(2), 141-146.
https://doi.org/10.1002/jcla.21658
Đunić I, Elezović I, Ilić V, Milošević-Jovčić N, Bila J, Suvajdžić-Vuković N, Antić D, Vidović A, Tomin D. The Effect of Paraprotein on Platelet Aggregation. in Journal of Clinical Laboratory Analysis. 2014;28(2):141-146.
doi:10.1002/jcla.21658 .
Đunić, Irena, Elezović, Ivo, Ilić, Vesna, Milošević-Jovčić, Nadežda, Bila, Jelena, Suvajdžić-Vuković, Nada, Antić, Darko, Vidović, Ana, Tomin, Dragica, "The Effect of Paraprotein on Platelet Aggregation" in Journal of Clinical Laboratory Analysis, 28, no. 2 (2014):141-146,
https://doi.org/10.1002/jcla.21658 . .
6
3
6

Specific Binding of Paraprotein to Platelet Receptors as a Cause of Platelet Dysfunction in Monoclonal Gammopathies

Đunić, I.; Elezović, Ivo; Vucić, M.; Srdić-Rajić, Tatjana; Konić-Ristić, Aleksandra; Ilić, Vesna; Milić, Nataša; Bila, Jelena; Suvajdžić-Vuković, Nada; Virijević, Marijana; Antić, Darko; Vidović, Ana; Tomin, Dragica

(Karger, Basel, 2013)

TY  - JOUR
AU  - Đunić, I.
AU  - Elezović, Ivo
AU  - Vucić, M.
AU  - Srdić-Rajić, Tatjana
AU  - Konić-Ristić, Aleksandra
AU  - Ilić, Vesna
AU  - Milić, Nataša
AU  - Bila, Jelena
AU  - Suvajdžić-Vuković, Nada
AU  - Virijević, Marijana
AU  - Antić, Darko
AU  - Vidović, Ana
AU  - Tomin, Dragica
PY  - 2013
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/510
AB  - The study included 48 untreated patients with monoclonal gammopathies (MG). Paraprotein was isolated from the serum of 10 patients with decreased platelet aggregation. Platelet aggregation was measured before and after the addition of the isolated paraprotein to platelet-rich plasma (PRP) from 10 healthy donors, in vitro. Expression of platelet von Willebrand factor (vWF) receptor glycoprotein (GP)Ib and platelet collagen receptor GPVI was determined by flow cytometry in the PRP of healthy donors before and after the addition of isolated paraprotein using the monoclonal antibodies, CD42b (for GPIb) and CD36 (for GPVI). Flowcytometry showed that expression of CD42b and CD36 positive cells was reduced after the addition of isolated paraprotein to PRP from healthy donors (p  lt  0.001). These investigations demonstrated that paraprotein causes platelet dysfunction in patients with MG due to specific binding to the platelet vWF receptor GPIb and platelet collagen receptor GPVI. Copyright (c) 2013 S. Karger AG, Basel
PB  - Karger, Basel
T2  - Acta Haematologica
T1  - Specific Binding of Paraprotein to Platelet Receptors as a Cause of Platelet Dysfunction in Monoclonal Gammopathies
EP  - 107
IS  - 2
SP  - 101
VL  - 130
DO  - 10.1159/000345418
ER  - 
@article{
author = "Đunić, I. and Elezović, Ivo and Vucić, M. and Srdić-Rajić, Tatjana and Konić-Ristić, Aleksandra and Ilić, Vesna and Milić, Nataša and Bila, Jelena and Suvajdžić-Vuković, Nada and Virijević, Marijana and Antić, Darko and Vidović, Ana and Tomin, Dragica",
year = "2013",
abstract = "The study included 48 untreated patients with monoclonal gammopathies (MG). Paraprotein was isolated from the serum of 10 patients with decreased platelet aggregation. Platelet aggregation was measured before and after the addition of the isolated paraprotein to platelet-rich plasma (PRP) from 10 healthy donors, in vitro. Expression of platelet von Willebrand factor (vWF) receptor glycoprotein (GP)Ib and platelet collagen receptor GPVI was determined by flow cytometry in the PRP of healthy donors before and after the addition of isolated paraprotein using the monoclonal antibodies, CD42b (for GPIb) and CD36 (for GPVI). Flowcytometry showed that expression of CD42b and CD36 positive cells was reduced after the addition of isolated paraprotein to PRP from healthy donors (p  lt  0.001). These investigations demonstrated that paraprotein causes platelet dysfunction in patients with MG due to specific binding to the platelet vWF receptor GPIb and platelet collagen receptor GPVI. Copyright (c) 2013 S. Karger AG, Basel",
publisher = "Karger, Basel",
journal = "Acta Haematologica",
title = "Specific Binding of Paraprotein to Platelet Receptors as a Cause of Platelet Dysfunction in Monoclonal Gammopathies",
pages = "107-101",
number = "2",
volume = "130",
doi = "10.1159/000345418"
}
Đunić, I., Elezović, I., Vucić, M., Srdić-Rajić, T., Konić-Ristić, A., Ilić, V., Milić, N., Bila, J., Suvajdžić-Vuković, N., Virijević, M., Antić, D., Vidović, A.,& Tomin, D.. (2013). Specific Binding of Paraprotein to Platelet Receptors as a Cause of Platelet Dysfunction in Monoclonal Gammopathies. in Acta Haematologica
Karger, Basel., 130(2), 101-107.
https://doi.org/10.1159/000345418
Đunić I, Elezović I, Vucić M, Srdić-Rajić T, Konić-Ristić A, Ilić V, Milić N, Bila J, Suvajdžić-Vuković N, Virijević M, Antić D, Vidović A, Tomin D. Specific Binding of Paraprotein to Platelet Receptors as a Cause of Platelet Dysfunction in Monoclonal Gammopathies. in Acta Haematologica. 2013;130(2):101-107.
doi:10.1159/000345418 .
Đunić, I., Elezović, Ivo, Vucić, M., Srdić-Rajić, Tatjana, Konić-Ristić, Aleksandra, Ilić, Vesna, Milić, Nataša, Bila, Jelena, Suvajdžić-Vuković, Nada, Virijević, Marijana, Antić, Darko, Vidović, Ana, Tomin, Dragica, "Specific Binding of Paraprotein to Platelet Receptors as a Cause of Platelet Dysfunction in Monoclonal Gammopathies" in Acta Haematologica, 130, no. 2 (2013):101-107,
https://doi.org/10.1159/000345418 . .
9
6
6

Paraprotein specific binding for platelet receptor glycoprotein Ib as a cause of acquired von Willebrand syndrome in monoclonal gammopathies

Đunić, I.; Elezović, Ivo; Vucić, M.; Srdić-Rajić, Tatjana; Konić-Ristić, Aleksandra; Ilić, Vesna; Milić, Nataša; Bila, J.; Suvajdžić-Vuković, Nada; Antić, Darko; Vidović, Ana; Tomin, Dragica

(Wiley-Blackwell, Hoboken, 2012)

TY  - CONF
AU  - Đunić, I.
AU  - Elezović, Ivo
AU  - Vucić, M.
AU  - Srdić-Rajić, Tatjana
AU  - Konić-Ristić, Aleksandra
AU  - Ilić, Vesna
AU  - Milić, Nataša
AU  - Bila, J.
AU  - Suvajdžić-Vuković, Nada
AU  - Antić, Darko
AU  - Vidović, Ana
AU  - Tomin, Dragica
PY  - 2012
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/416
PB  - Wiley-Blackwell, Hoboken
C3  - Haemophilia
T1  - Paraprotein specific binding for platelet receptor glycoprotein Ib as a cause of acquired von Willebrand syndrome in monoclonal gammopathies
EP  - 195
SP  - 195
VL  - 18
UR  - https://hdl.handle.net/21.15107/rcub_rimi_416
ER  - 
@conference{
author = "Đunić, I. and Elezović, Ivo and Vucić, M. and Srdić-Rajić, Tatjana and Konić-Ristić, Aleksandra and Ilić, Vesna and Milić, Nataša and Bila, J. and Suvajdžić-Vuković, Nada and Antić, Darko and Vidović, Ana and Tomin, Dragica",
year = "2012",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Haemophilia",
title = "Paraprotein specific binding for platelet receptor glycoprotein Ib as a cause of acquired von Willebrand syndrome in monoclonal gammopathies",
pages = "195-195",
volume = "18",
url = "https://hdl.handle.net/21.15107/rcub_rimi_416"
}
Đunić, I., Elezović, I., Vucić, M., Srdić-Rajić, T., Konić-Ristić, A., Ilić, V., Milić, N., Bila, J., Suvajdžić-Vuković, N., Antić, D., Vidović, A.,& Tomin, D.. (2012). Paraprotein specific binding for platelet receptor glycoprotein Ib as a cause of acquired von Willebrand syndrome in monoclonal gammopathies. in Haemophilia
Wiley-Blackwell, Hoboken., 18, 195-195.
https://hdl.handle.net/21.15107/rcub_rimi_416
Đunić I, Elezović I, Vucić M, Srdić-Rajić T, Konić-Ristić A, Ilić V, Milić N, Bila J, Suvajdžić-Vuković N, Antić D, Vidović A, Tomin D. Paraprotein specific binding for platelet receptor glycoprotein Ib as a cause of acquired von Willebrand syndrome in monoclonal gammopathies. in Haemophilia. 2012;18:195-195.
https://hdl.handle.net/21.15107/rcub_rimi_416 .
Đunić, I., Elezović, Ivo, Vucić, M., Srdić-Rajić, Tatjana, Konić-Ristić, Aleksandra, Ilić, Vesna, Milić, Nataša, Bila, J., Suvajdžić-Vuković, Nada, Antić, Darko, Vidović, Ana, Tomin, Dragica, "Paraprotein specific binding for platelet receptor glycoprotein Ib as a cause of acquired von Willebrand syndrome in monoclonal gammopathies" in Haemophilia, 18 (2012):195-195,
https://hdl.handle.net/21.15107/rcub_rimi_416 .

Platelets dysfunction in multiple myeloma

Đunić, I.; Elezović, Ivo; Ilić, Vesna; Tomin, Dragica; Bila, J.; Suvajdžić-Vuković, Nada; Antić, Darko; Vidović, Ana; Milošević-Jovčić, Nadežda

(Pergamon-Elsevier Science Ltd, Oxford, 2012)

TY  - CONF
AU  - Đunić, I.
AU  - Elezović, Ivo
AU  - Ilić, Vesna
AU  - Tomin, Dragica
AU  - Bila, J.
AU  - Suvajdžić-Vuković, Nada
AU  - Antić, Darko
AU  - Vidović, Ana
AU  - Milošević-Jovčić, Nadežda
PY  - 2012
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/429
PB  - Pergamon-Elsevier Science Ltd, Oxford
C3  - Thrombosis Research
T1  - Platelets dysfunction in multiple myeloma
EP  - S173
SP  - S173
VL  - 129
DO  - 10.1016/S0049-3848(12)70082-8
ER  - 
@conference{
author = "Đunić, I. and Elezović, Ivo and Ilić, Vesna and Tomin, Dragica and Bila, J. and Suvajdžić-Vuković, Nada and Antić, Darko and Vidović, Ana and Milošević-Jovčić, Nadežda",
year = "2012",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Platelets dysfunction in multiple myeloma",
pages = "S173-S173",
volume = "129",
doi = "10.1016/S0049-3848(12)70082-8"
}
Đunić, I., Elezović, I., Ilić, V., Tomin, D., Bila, J., Suvajdžić-Vuković, N., Antić, D., Vidović, A.,& Milošević-Jovčić, N.. (2012). Platelets dysfunction in multiple myeloma. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 129, S173-S173.
https://doi.org/10.1016/S0049-3848(12)70082-8
Đunić I, Elezović I, Ilić V, Tomin D, Bila J, Suvajdžić-Vuković N, Antić D, Vidović A, Milošević-Jovčić N. Platelets dysfunction in multiple myeloma. in Thrombosis Research. 2012;129:S173-S173.
doi:10.1016/S0049-3848(12)70082-8 .
Đunić, I., Elezović, Ivo, Ilić, Vesna, Tomin, Dragica, Bila, J., Suvajdžić-Vuković, Nada, Antić, Darko, Vidović, Ana, Milošević-Jovčić, Nadežda, "Platelets dysfunction in multiple myeloma" in Thrombosis Research, 129 (2012):S173-S173,
https://doi.org/10.1016/S0049-3848(12)70082-8 . .

Specific binding of paraprotein to platelet receptors as a cause of platelet disfunction in monoclonal gammopathies

Đunić, I.; Elezović, Ivo; Vucić, M.; Srdić-Rajić, Tatjana; Konić-Ristić, Aleksandra; Ilić, Vesna; Milić, Nataša; Bila, J.; Suvajdžić-Vuković, Nada; Virijević, Marijana; Antić, Darko; Vidović, Ana; Tomin, Dragica

(Ferrata Storti Foundation, Pavia, 2012)

TY  - CONF
AU  - Đunić, I.
AU  - Elezović, Ivo
AU  - Vucić, M.
AU  - Srdić-Rajić, Tatjana
AU  - Konić-Ristić, Aleksandra
AU  - Ilić, Vesna
AU  - Milić, Nataša
AU  - Bila, J.
AU  - Suvajdžić-Vuković, Nada
AU  - Virijević, Marijana
AU  - Antić, Darko
AU  - Vidović, Ana
AU  - Tomin, Dragica
PY  - 2012
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/452
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - Specific binding of paraprotein to platelet receptors as a cause of platelet disfunction in monoclonal gammopathies
EP  - 197
SP  - 196
VL  - 97
UR  - https://hdl.handle.net/21.15107/rcub_rimi_452
ER  - 
@conference{
author = "Đunić, I. and Elezović, Ivo and Vucić, M. and Srdić-Rajić, Tatjana and Konić-Ristić, Aleksandra and Ilić, Vesna and Milić, Nataša and Bila, J. and Suvajdžić-Vuković, Nada and Virijević, Marijana and Antić, Darko and Vidović, Ana and Tomin, Dragica",
year = "2012",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "Specific binding of paraprotein to platelet receptors as a cause of platelet disfunction in monoclonal gammopathies",
pages = "197-196",
volume = "97",
url = "https://hdl.handle.net/21.15107/rcub_rimi_452"
}
Đunić, I., Elezović, I., Vucić, M., Srdić-Rajić, T., Konić-Ristić, A., Ilić, V., Milić, N., Bila, J., Suvajdžić-Vuković, N., Virijević, M., Antić, D., Vidović, A.,& Tomin, D.. (2012). Specific binding of paraprotein to platelet receptors as a cause of platelet disfunction in monoclonal gammopathies. in Haematologica
Ferrata Storti Foundation, Pavia., 97, 196-197.
https://hdl.handle.net/21.15107/rcub_rimi_452
Đunić I, Elezović I, Vucić M, Srdić-Rajić T, Konić-Ristić A, Ilić V, Milić N, Bila J, Suvajdžić-Vuković N, Virijević M, Antić D, Vidović A, Tomin D. Specific binding of paraprotein to platelet receptors as a cause of platelet disfunction in monoclonal gammopathies. in Haematologica. 2012;97:196-197.
https://hdl.handle.net/21.15107/rcub_rimi_452 .
Đunić, I., Elezović, Ivo, Vucić, M., Srdić-Rajić, Tatjana, Konić-Ristić, Aleksandra, Ilić, Vesna, Milić, Nataša, Bila, J., Suvajdžić-Vuković, Nada, Virijević, Marijana, Antić, Darko, Vidović, Ana, Tomin, Dragica, "Specific binding of paraprotein to platelet receptors as a cause of platelet disfunction in monoclonal gammopathies" in Haematologica, 97 (2012):196-197,
https://hdl.handle.net/21.15107/rcub_rimi_452 .

Significance of new prognostic markers in early stage chronic lymphocytic leukemia patients

Antić, Darko; Mihaljević, Biljana; Čokić, Vladan; Dencic-Fekete, Marija; Karan-Đurašević, Teodora; Pavlović, S.; Milić, Nataša; Elezović, Ivo

(Elsevier, Amsterdam, 2011)

TY  - CONF
AU  - Antić, Darko
AU  - Mihaljević, Biljana
AU  - Čokić, Vladan
AU  - Dencic-Fekete, Marija
AU  - Karan-Đurašević, Teodora
AU  - Pavlović, S.
AU  - Milić, Nataša
AU  - Elezović, Ivo
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/332
PB  - Elsevier, Amsterdam
C3  - Annals of Oncology
T1  - Significance of new prognostic markers in early stage chronic lymphocytic leukemia patients
EP  - 242
SP  - 242
VL  - 22
UR  - https://hdl.handle.net/21.15107/rcub_rimi_332
ER  - 
@conference{
author = "Antić, Darko and Mihaljević, Biljana and Čokić, Vladan and Dencic-Fekete, Marija and Karan-Đurašević, Teodora and Pavlović, S. and Milić, Nataša and Elezović, Ivo",
year = "2011",
publisher = "Elsevier, Amsterdam",
journal = "Annals of Oncology",
title = "Significance of new prognostic markers in early stage chronic lymphocytic leukemia patients",
pages = "242-242",
volume = "22",
url = "https://hdl.handle.net/21.15107/rcub_rimi_332"
}
Antić, D., Mihaljević, B., Čokić, V., Dencic-Fekete, M., Karan-Đurašević, T., Pavlović, S., Milić, N.,& Elezović, I.. (2011). Significance of new prognostic markers in early stage chronic lymphocytic leukemia patients. in Annals of Oncology
Elsevier, Amsterdam., 22, 242-242.
https://hdl.handle.net/21.15107/rcub_rimi_332
Antić D, Mihaljević B, Čokić V, Dencic-Fekete M, Karan-Đurašević T, Pavlović S, Milić N, Elezović I. Significance of new prognostic markers in early stage chronic lymphocytic leukemia patients. in Annals of Oncology. 2011;22:242-242.
https://hdl.handle.net/21.15107/rcub_rimi_332 .
Antić, Darko, Mihaljević, Biljana, Čokić, Vladan, Dencic-Fekete, Marija, Karan-Đurašević, Teodora, Pavlović, S., Milić, Nataša, Elezović, Ivo, "Significance of new prognostic markers in early stage chronic lymphocytic leukemia patients" in Annals of Oncology, 22 (2011):242-242,
https://hdl.handle.net/21.15107/rcub_rimi_332 .

Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling

Antić, Darko; Mihaljević, Biljana; Čokić, Vladan; Dencic-Fekete, Marija; Karan-Đurašević, Teodora; Pavlović, Sonja; Milić, Nataša; Elezović, Ivo

(Taylor & Francis Ltd, Abingdon, 2011)

TY  - JOUR
AU  - Antić, Darko
AU  - Mihaljević, Biljana
AU  - Čokić, Vladan
AU  - Dencic-Fekete, Marija
AU  - Karan-Đurašević, Teodora
AU  - Pavlović, Sonja
AU  - Milić, Nataša
AU  - Elezović, Ivo
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/336
AB  - We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p  lt  0.0001).
PB  - Taylor & Francis Ltd, Abingdon
T2  - Leukemia & Lymphoma
T1  - Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling
EP  - 1397
IS  - 7
SP  - 1394
VL  - 52
DO  - 10.3109/10428194.2011.578311
ER  - 
@article{
author = "Antić, Darko and Mihaljević, Biljana and Čokić, Vladan and Dencic-Fekete, Marija and Karan-Đurašević, Teodora and Pavlović, Sonja and Milić, Nataša and Elezović, Ivo",
year = "2011",
abstract = "We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p  lt  0.0001).",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Leukemia & Lymphoma",
title = "Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling",
pages = "1397-1394",
number = "7",
volume = "52",
doi = "10.3109/10428194.2011.578311"
}
Antić, D., Mihaljević, B., Čokić, V., Dencic-Fekete, M., Karan-Đurašević, T., Pavlović, S., Milić, N.,& Elezović, I.. (2011). Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. in Leukemia & Lymphoma
Taylor & Francis Ltd, Abingdon., 52(7), 1394-1397.
https://doi.org/10.3109/10428194.2011.578311
Antić D, Mihaljević B, Čokić V, Dencic-Fekete M, Karan-Đurašević T, Pavlović S, Milić N, Elezović I. Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. in Leukemia & Lymphoma. 2011;52(7):1394-1397.
doi:10.3109/10428194.2011.578311 .
Antić, Darko, Mihaljević, Biljana, Čokić, Vladan, Dencic-Fekete, Marija, Karan-Đurašević, Teodora, Pavlović, Sonja, Milić, Nataša, Elezović, Ivo, "Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling" in Leukemia & Lymphoma, 52, no. 7 (2011):1394-1397,
https://doi.org/10.3109/10428194.2011.578311 . .
6
5
5

Acquired von Willebrand syndrome in multiple myeloma

Đunić, Irena; Elezović, Ivo; Ilić, Vesna; Tomin, Dragica; Suvajdžić-Vuković, Nada; Bila, Jelena; Antić, Darko; Vidović, Ana; Milošević-Jovčić, Nadežda

(Taylor & Francis Ltd, Abingdon, 2011)

TY  - JOUR
AU  - Đunić, Irena
AU  - Elezović, Ivo
AU  - Ilić, Vesna
AU  - Tomin, Dragica
AU  - Suvajdžić-Vuković, Nada
AU  - Bila, Jelena
AU  - Antić, Darko
AU  - Vidović, Ana
AU  - Milošević-Jovčić, Nadežda
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/326
AB  - Acquired von Willebrand syndrome (AvWS) is an uncommon complication of multiple myeloma (MM), and it is believed to be connected with paraprotein. The aim of this study was to determine the incidence of AvWS in patients with MM, and estimate the role of paraprotein in its occurrence. The study included 40 patients with MM. The plasma level of paraprotein, platelet adhesion on glass pearls, plasma von Willebrand factor antigen concentration, and ristocetin-induced platelet aggregation (RIPA) were measured initially. Absence of RIPA was found in six patients with MM (15%); however, all six of them had normal levels of von Willebrand factor antigen. Paraprotein was isolated from the serum of these patients. Platelet aggregation was measured in six healthy donors before and after addition of the isolated paraprotein. RIPA was significantly decreased in healthy donors in the presence of paraprotein (P  lt  0.001). The same test was repeated with added human immunoglobulins for intravenous use without any change in RIPA. A significant negative correlation between plasma paraprotein level and RIPA was found (P  lt  0.001). These investigations have shown that paraprotein is associated with AvWS in patients with MM.
PB  - Taylor & Francis Ltd, Abingdon
T2  - Hematology
T1  - Acquired von Willebrand syndrome in multiple myeloma
EP  - 212
IS  - 4
SP  - 209
VL  - 16
DO  - 10.1179/102453311X12953015767617
ER  - 
@article{
author = "Đunić, Irena and Elezović, Ivo and Ilić, Vesna and Tomin, Dragica and Suvajdžić-Vuković, Nada and Bila, Jelena and Antić, Darko and Vidović, Ana and Milošević-Jovčić, Nadežda",
year = "2011",
abstract = "Acquired von Willebrand syndrome (AvWS) is an uncommon complication of multiple myeloma (MM), and it is believed to be connected with paraprotein. The aim of this study was to determine the incidence of AvWS in patients with MM, and estimate the role of paraprotein in its occurrence. The study included 40 patients with MM. The plasma level of paraprotein, platelet adhesion on glass pearls, plasma von Willebrand factor antigen concentration, and ristocetin-induced platelet aggregation (RIPA) were measured initially. Absence of RIPA was found in six patients with MM (15%); however, all six of them had normal levels of von Willebrand factor antigen. Paraprotein was isolated from the serum of these patients. Platelet aggregation was measured in six healthy donors before and after addition of the isolated paraprotein. RIPA was significantly decreased in healthy donors in the presence of paraprotein (P  lt  0.001). The same test was repeated with added human immunoglobulins for intravenous use without any change in RIPA. A significant negative correlation between plasma paraprotein level and RIPA was found (P  lt  0.001). These investigations have shown that paraprotein is associated with AvWS in patients with MM.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Hematology",
title = "Acquired von Willebrand syndrome in multiple myeloma",
pages = "212-209",
number = "4",
volume = "16",
doi = "10.1179/102453311X12953015767617"
}
Đunić, I., Elezović, I., Ilić, V., Tomin, D., Suvajdžić-Vuković, N., Bila, J., Antić, D., Vidović, A.,& Milošević-Jovčić, N.. (2011). Acquired von Willebrand syndrome in multiple myeloma. in Hematology
Taylor & Francis Ltd, Abingdon., 16(4), 209-212.
https://doi.org/10.1179/102453311X12953015767617
Đunić I, Elezović I, Ilić V, Tomin D, Suvajdžić-Vuković N, Bila J, Antić D, Vidović A, Milošević-Jovčić N. Acquired von Willebrand syndrome in multiple myeloma. in Hematology. 2011;16(4):209-212.
doi:10.1179/102453311X12953015767617 .
Đunić, Irena, Elezović, Ivo, Ilić, Vesna, Tomin, Dragica, Suvajdžić-Vuković, Nada, Bila, Jelena, Antić, Darko, Vidović, Ana, Milošević-Jovčić, Nadežda, "Acquired von Willebrand syndrome in multiple myeloma" in Hematology, 16, no. 4 (2011):209-212,
https://doi.org/10.1179/102453311X12953015767617 . .
7
3
6

Microarray and Proteomic Analysis of Myeloproliferative Neoplasms

Čokić, Vladan; Mossuz, Pascal; Han, Jing; Diklić, Miloš; Budeč, Mirela; Sefer, Dijana; Leković, Danijela; Antić, Darko; Breković, Tijana; Mojsilović, Sonja; Puri, Raj K.; Noguchi, Constance T.; Schechter, Alan N.

(Amer Soc Hematology, Washington, 2011)

TY  - CONF
AU  - Čokić, Vladan
AU  - Mossuz, Pascal
AU  - Han, Jing
AU  - Diklić, Miloš
AU  - Budeč, Mirela
AU  - Sefer, Dijana
AU  - Leković, Danijela
AU  - Antić, Darko
AU  - Breković, Tijana
AU  - Mojsilović, Sonja
AU  - Puri, Raj K.
AU  - Noguchi, Constance T.
AU  - Schechter, Alan N.
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/348
PB  - Amer Soc Hematology, Washington
C3  - Blood
T1  - Microarray and Proteomic Analysis of Myeloproliferative Neoplasms
EP  - 1649
IS  - 21
SP  - 1649
VL  - 118
UR  - https://hdl.handle.net/21.15107/rcub_rimi_348
ER  - 
@conference{
author = "Čokić, Vladan and Mossuz, Pascal and Han, Jing and Diklić, Miloš and Budeč, Mirela and Sefer, Dijana and Leković, Danijela and Antić, Darko and Breković, Tijana and Mojsilović, Sonja and Puri, Raj K. and Noguchi, Constance T. and Schechter, Alan N.",
year = "2011",
publisher = "Amer Soc Hematology, Washington",
journal = "Blood",
title = "Microarray and Proteomic Analysis of Myeloproliferative Neoplasms",
pages = "1649-1649",
number = "21",
volume = "118",
url = "https://hdl.handle.net/21.15107/rcub_rimi_348"
}
Čokić, V., Mossuz, P., Han, J., Diklić, M., Budeč, M., Sefer, D., Leković, D., Antić, D., Breković, T., Mojsilović, S., Puri, R. K., Noguchi, C. T.,& Schechter, A. N.. (2011). Microarray and Proteomic Analysis of Myeloproliferative Neoplasms. in Blood
Amer Soc Hematology, Washington., 118(21), 1649-1649.
https://hdl.handle.net/21.15107/rcub_rimi_348
Čokić V, Mossuz P, Han J, Diklić M, Budeč M, Sefer D, Leković D, Antić D, Breković T, Mojsilović S, Puri RK, Noguchi CT, Schechter AN. Microarray and Proteomic Analysis of Myeloproliferative Neoplasms. in Blood. 2011;118(21):1649-1649.
https://hdl.handle.net/21.15107/rcub_rimi_348 .
Čokić, Vladan, Mossuz, Pascal, Han, Jing, Diklić, Miloš, Budeč, Mirela, Sefer, Dijana, Leković, Danijela, Antić, Darko, Breković, Tijana, Mojsilović, Sonja, Puri, Raj K., Noguchi, Constance T., Schechter, Alan N., "Microarray and Proteomic Analysis of Myeloproliferative Neoplasms" in Blood, 118, no. 21 (2011):1649-1649,
https://hdl.handle.net/21.15107/rcub_rimi_348 .

Acquired von Willebrand Syndrome in women with monoclonal gammopathies

Đunić, I.; Elezović, Ivo; Ilić, Vesna; Tomin, Dragica; Suvajdžić-Vuković, Nada; Antić, Darko; Bila, J.; Vidović, Ana; Milošević-Jovčić, Nadežda

(Pergamon-Elsevier Science Ltd, Oxford, 2011)

TY  - CONF
AU  - Đunić, I.
AU  - Elezović, Ivo
AU  - Ilić, Vesna
AU  - Tomin, Dragica
AU  - Suvajdžić-Vuković, Nada
AU  - Antić, Darko
AU  - Bila, J.
AU  - Vidović, Ana
AU  - Milošević-Jovčić, Nadežda
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/377
PB  - Pergamon-Elsevier Science Ltd, Oxford
C3  - Thrombosis Research
T1  - Acquired von Willebrand Syndrome in women with monoclonal gammopathies
EP  - S141
SP  - S141
VL  - 127
DO  - 10.1016/S0049-3848(11)70106-2
ER  - 
@conference{
author = "Đunić, I. and Elezović, Ivo and Ilić, Vesna and Tomin, Dragica and Suvajdžić-Vuković, Nada and Antić, Darko and Bila, J. and Vidović, Ana and Milošević-Jovčić, Nadežda",
year = "2011",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Acquired von Willebrand Syndrome in women with monoclonal gammopathies",
pages = "S141-S141",
volume = "127",
doi = "10.1016/S0049-3848(11)70106-2"
}
Đunić, I., Elezović, I., Ilić, V., Tomin, D., Suvajdžić-Vuković, N., Antić, D., Bila, J., Vidović, A.,& Milošević-Jovčić, N.. (2011). Acquired von Willebrand Syndrome in women with monoclonal gammopathies. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 127, S141-S141.
https://doi.org/10.1016/S0049-3848(11)70106-2
Đunić I, Elezović I, Ilić V, Tomin D, Suvajdžić-Vuković N, Antić D, Bila J, Vidović A, Milošević-Jovčić N. Acquired von Willebrand Syndrome in women with monoclonal gammopathies. in Thrombosis Research. 2011;127:S141-S141.
doi:10.1016/S0049-3848(11)70106-2 .
Đunić, I., Elezović, Ivo, Ilić, Vesna, Tomin, Dragica, Suvajdžić-Vuković, Nada, Antić, Darko, Bila, J., Vidović, Ana, Milošević-Jovčić, Nadežda, "Acquired von Willebrand Syndrome in women with monoclonal gammopathies" in Thrombosis Research, 127 (2011):S141-S141,
https://doi.org/10.1016/S0049-3848(11)70106-2 . .

Prognostic value of vascular endothelial growth factor (VEGF) serum level and immunohistochemical expression in non-treated patient with chronic lymphocytic leukemia

Antić, Darko; Dencic-Fekete, Marija; Čokić, Vladan; Jovanović, M. P.; Dragović, T.; Mihaljević, Biljana

(Pergamon-Elsevier Science Ltd, Oxford, 2010)

TY  - CONF
AU  - Antić, Darko
AU  - Dencic-Fekete, Marija
AU  - Čokić, Vladan
AU  - Jovanović, M. P.
AU  - Dragović, T.
AU  - Mihaljević, Biljana
PY  - 2010
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/292
PB  - Pergamon-Elsevier Science Ltd, Oxford
C3  - Thrombosis Research
T1  - Prognostic value of vascular endothelial growth factor (VEGF) serum level and immunohistochemical expression in non-treated patient with chronic lymphocytic leukemia
EP  - S189
SP  - S189
VL  - 125
DO  - 10.1016/S0049-3848(10)70137-7
ER  - 
@conference{
author = "Antić, Darko and Dencic-Fekete, Marija and Čokić, Vladan and Jovanović, M. P. and Dragović, T. and Mihaljević, Biljana",
year = "2010",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Prognostic value of vascular endothelial growth factor (VEGF) serum level and immunohistochemical expression in non-treated patient with chronic lymphocytic leukemia",
pages = "S189-S189",
volume = "125",
doi = "10.1016/S0049-3848(10)70137-7"
}
Antić, D., Dencic-Fekete, M., Čokić, V., Jovanović, M. P., Dragović, T.,& Mihaljević, B.. (2010). Prognostic value of vascular endothelial growth factor (VEGF) serum level and immunohistochemical expression in non-treated patient with chronic lymphocytic leukemia. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 125, S189-S189.
https://doi.org/10.1016/S0049-3848(10)70137-7
Antić D, Dencic-Fekete M, Čokić V, Jovanović MP, Dragović T, Mihaljević B. Prognostic value of vascular endothelial growth factor (VEGF) serum level and immunohistochemical expression in non-treated patient with chronic lymphocytic leukemia. in Thrombosis Research. 2010;125:S189-S189.
doi:10.1016/S0049-3848(10)70137-7 .
Antić, Darko, Dencic-Fekete, Marija, Čokić, Vladan, Jovanović, M. P., Dragović, T., Mihaljević, Biljana, "Prognostic value of vascular endothelial growth factor (VEGF) serum level and immunohistochemical expression in non-treated patient with chronic lymphocytic leukemia" in Thrombosis Research, 125 (2010):S189-S189,
https://doi.org/10.1016/S0049-3848(10)70137-7 . .

Serum level of vascular endothelial growth factor (vegf) as prognostic parameter in untreated patients with b-cell chronic lymphocytic leukemia

Antić, Darko; Čokić, Vladan; Dencic-Fekete, Marija; Peruničić-Jovanović, Maja; Ević, V. Milo; Kraguljac-Kurtović, Nada

(Ferrata Storti Foundation, Pavia, 2010)

TY  - CONF
AU  - Antić, Darko
AU  - Čokić, Vladan
AU  - Dencic-Fekete, Marija
AU  - Peruničić-Jovanović, Maja
AU  - Ević, V. Milo
AU  - Kraguljac-Kurtović, Nada
PY  - 2010
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/302
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - Serum level of vascular endothelial growth factor (vegf) as prognostic parameter in untreated patients with b-cell chronic lymphocytic leukemia
EP  - 524
SP  - 524
VL  - 95
UR  - https://hdl.handle.net/21.15107/rcub_rimi_302
ER  - 
@conference{
author = "Antić, Darko and Čokić, Vladan and Dencic-Fekete, Marija and Peruničić-Jovanović, Maja and Ević, V. Milo and Kraguljac-Kurtović, Nada",
year = "2010",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "Serum level of vascular endothelial growth factor (vegf) as prognostic parameter in untreated patients with b-cell chronic lymphocytic leukemia",
pages = "524-524",
volume = "95",
url = "https://hdl.handle.net/21.15107/rcub_rimi_302"
}
Antić, D., Čokić, V., Dencic-Fekete, M., Peruničić-Jovanović, M., Ević, V. M.,& Kraguljac-Kurtović, N.. (2010). Serum level of vascular endothelial growth factor (vegf) as prognostic parameter in untreated patients with b-cell chronic lymphocytic leukemia. in Haematologica
Ferrata Storti Foundation, Pavia., 95, 524-524.
https://hdl.handle.net/21.15107/rcub_rimi_302
Antić D, Čokić V, Dencic-Fekete M, Peruničić-Jovanović M, Ević VM, Kraguljac-Kurtović N. Serum level of vascular endothelial growth factor (vegf) as prognostic parameter in untreated patients with b-cell chronic lymphocytic leukemia. in Haematologica. 2010;95:524-524.
https://hdl.handle.net/21.15107/rcub_rimi_302 .
Antić, Darko, Čokić, Vladan, Dencic-Fekete, Marija, Peruničić-Jovanović, Maja, Ević, V. Milo, Kraguljac-Kurtović, Nada, "Serum level of vascular endothelial growth factor (vegf) as prognostic parameter in untreated patients with b-cell chronic lymphocytic leukemia" in Haematologica, 95 (2010):524-524,
https://hdl.handle.net/21.15107/rcub_rimi_302 .

Disturbances of platelets aggregation in patients with multiple myeloma

Đunić, I.; Elezović, Ivo; Tomin, Dragica; Ilić, Vesna; Suvajdžić-Vuković, Nada; Bila, J.; Antić, Darko; Vidović, Ana; Milošević-Jovčić, Nadežda

(Ferrata Storti Foundation, Pavia, 2010)

TY  - CONF
AU  - Đunić, I.
AU  - Elezović, Ivo
AU  - Tomin, Dragica
AU  - Ilić, Vesna
AU  - Suvajdžić-Vuković, Nada
AU  - Bila, J.
AU  - Antić, Darko
AU  - Vidović, Ana
AU  - Milošević-Jovčić, Nadežda
PY  - 2010
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/305
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - Disturbances of platelets aggregation in patients with multiple myeloma
EP  - 749
SP  - 749
VL  - 95
UR  - https://hdl.handle.net/21.15107/rcub_rimi_305
ER  - 
@conference{
author = "Đunić, I. and Elezović, Ivo and Tomin, Dragica and Ilić, Vesna and Suvajdžić-Vuković, Nada and Bila, J. and Antić, Darko and Vidović, Ana and Milošević-Jovčić, Nadežda",
year = "2010",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "Disturbances of platelets aggregation in patients with multiple myeloma",
pages = "749-749",
volume = "95",
url = "https://hdl.handle.net/21.15107/rcub_rimi_305"
}
Đunić, I., Elezović, I., Tomin, D., Ilić, V., Suvajdžić-Vuković, N., Bila, J., Antić, D., Vidović, A.,& Milošević-Jovčić, N.. (2010). Disturbances of platelets aggregation in patients with multiple myeloma. in Haematologica
Ferrata Storti Foundation, Pavia., 95, 749-749.
https://hdl.handle.net/21.15107/rcub_rimi_305
Đunić I, Elezović I, Tomin D, Ilić V, Suvajdžić-Vuković N, Bila J, Antić D, Vidović A, Milošević-Jovčić N. Disturbances of platelets aggregation in patients with multiple myeloma. in Haematologica. 2010;95:749-749.
https://hdl.handle.net/21.15107/rcub_rimi_305 .
Đunić, I., Elezović, Ivo, Tomin, Dragica, Ilić, Vesna, Suvajdžić-Vuković, Nada, Bila, J., Antić, Darko, Vidović, Ana, Milošević-Jovčić, Nadežda, "Disturbances of platelets aggregation in patients with multiple myeloma" in Haematologica, 95 (2010):749-749,
https://hdl.handle.net/21.15107/rcub_rimi_305 .

Acquired von Willebrand syndrome in monoclonal gammopathies

Đunić, I.; Elezović, Ivo; Tomin, Dragica; Antić, Darko; Ilić, Vesna; Milošević-Jovčić, Nadežda

(Wiley-Blackwell Publishing, Inc, Malden, 2010)

TY  - CONF
AU  - Đunić, I.
AU  - Elezović, Ivo
AU  - Tomin, Dragica
AU  - Antić, Darko
AU  - Ilić, Vesna
AU  - Milošević-Jovčić, Nadežda
PY  - 2010
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/309
PB  - Wiley-Blackwell Publishing, Inc, Malden
C3  - Haemophilia
T1  - Acquired von Willebrand syndrome in monoclonal gammopathies
EP  - 148
SP  - 148
VL  - 16
UR  - https://hdl.handle.net/21.15107/rcub_rimi_309
ER  - 
@conference{
author = "Đunić, I. and Elezović, Ivo and Tomin, Dragica and Antić, Darko and Ilić, Vesna and Milošević-Jovčić, Nadežda",
year = "2010",
publisher = "Wiley-Blackwell Publishing, Inc, Malden",
journal = "Haemophilia",
title = "Acquired von Willebrand syndrome in monoclonal gammopathies",
pages = "148-148",
volume = "16",
url = "https://hdl.handle.net/21.15107/rcub_rimi_309"
}
Đunić, I., Elezović, I., Tomin, D., Antić, D., Ilić, V.,& Milošević-Jovčić, N.. (2010). Acquired von Willebrand syndrome in monoclonal gammopathies. in Haemophilia
Wiley-Blackwell Publishing, Inc, Malden., 16, 148-148.
https://hdl.handle.net/21.15107/rcub_rimi_309
Đunić I, Elezović I, Tomin D, Antić D, Ilić V, Milošević-Jovčić N. Acquired von Willebrand syndrome in monoclonal gammopathies. in Haemophilia. 2010;16:148-148.
https://hdl.handle.net/21.15107/rcub_rimi_309 .
Đunić, I., Elezović, Ivo, Tomin, Dragica, Antić, Darko, Ilić, Vesna, Milošević-Jovčić, Nadežda, "Acquired von Willebrand syndrome in monoclonal gammopathies" in Haemophilia, 16 (2010):148-148,
https://hdl.handle.net/21.15107/rcub_rimi_309 .